Reaction

Increased Viscosity Of Bronchial Secretion reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 624 reports · 20 co-occurring drugs

As of the last recalculation, Increased Viscosity Of Bronchial Secretion appears in 624 FAERS reports alongside 20 co-occurring drug terms. The strongest observed disproportionality signal is AMIKACIN (PRR 106.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Amikacin50106.2106.5
Elexacaftor, Tezacaftor, And Ivacaftor3084.284.4
Tobramycin Solution1954.454.5
Dornase Alfa3053.653.6
Tobramycin Sulfate1952.852.8
Tobramycin3449.849.9
Ivacaftor938.338.4
Theophylline1029.529.5
Theophylline Anhydrous1027.327.3
Omalizumab6025.925.9
Rifampin1125.625.6
Fluticasone Propionate And Salmeterol Xinafoate4224.925.0
Lumacaftor And Ivacaftor623.623.6
Mepolizumab3323.323.3
Nintedanib2123.123.1
Benzonatate1020.520.5
Fluticasone Propionate And Salmeterol2218.218.2
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate1714.014.0
Pirfenidone75.85.8
Nirmatrelvir And Ritonavir63.73.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.